IQVIA launches IQVIA Biotech
IQVIA plans to deliver tailored clinical and commercial solutions for small biotech and biopharma companies through its newly launched IQVIA Biotech solutions suite.
IQVIA Biotech, supported by more than 1,000 dedicated employees, will deliver simplified operating procedures, specialized teams, and services to provide a more agile way for these innovators to reach their drug development and commercialization milestones, the company said.
“We designed this comprehensive solutions suite to address what our biotech customers were asking for — transparent and fit-for-purpose clinical processes with dedicated, therapeutically aligned partners coupled with our unique set of enterprise capabilities,” IQVIA CEO and chairman Ari Bousbib said.
Bousbib continued, “Those end-to-end capabilities include the analytics, technology and human capital clients need to smartly plan the launch and commercialization pre- and post-approval of their products and the real world evidence needed to support pricing, safety, compliance, and regulatory requirements. We combine two decades of institutional experience specifically serving emerging biopharma companies with the power of the IQVIA Core to focus on the immediate goals of our biotech customers.”
“Biotech companies are advancing the drug development pipeline forward, and when they succeed, we all succeed,” IQVIA president, research and development solutions Richard Staub said. “By launching IQVIA Biotech as the first-of-its-kind global business, we can support biotech clients with local teams and our full suite of capabilities from molecule to market.”
IQVIA Biotech, supported by more than 1,000 dedicated employees, will deliver simplified operating procedures, specialized teams, and services to provide a more agile way for these innovators to reach their drug development and commercialization milestones, the company said.
“We designed this comprehensive solutions suite to address what our biotech customers were asking for — transparent and fit-for-purpose clinical processes with dedicated, therapeutically aligned partners coupled with our unique set of enterprise capabilities,” IQVIA CEO and chairman Ari Bousbib said.
Bousbib continued, “Those end-to-end capabilities include the analytics, technology and human capital clients need to smartly plan the launch and commercialization pre- and post-approval of their products and the real world evidence needed to support pricing, safety, compliance, and regulatory requirements. We combine two decades of institutional experience specifically serving emerging biopharma companies with the power of the IQVIA Core to focus on the immediate goals of our biotech customers.”
“Biotech companies are advancing the drug development pipeline forward, and when they succeed, we all succeed,” IQVIA president, research and development solutions Richard Staub said. “By launching IQVIA Biotech as the first-of-its-kind global business, we can support biotech clients with local teams and our full suite of capabilities from molecule to market.”